Pharma BD Deal Intelligence

Odyssey Therapeutics, Inc. / Evotec SE

2026 · Co-Development · Complete

On 2026-08-05 Evotec and Odyssey Therapeutics entered a strategic AI-enabled R&D collaboration in autoimmune and inflammatory diseases. Odyssey will apply Evotec's integrated data-driven discovery platform, screening capabilities, proprietary compound libraries and AI data-science technologies to discover and validate differentiated small-molecule candidates across multiple discovery-stage targets. Evotec is eligible for milestone payments tied to delivery of validated hit series for each target; detailed financial terms were not disclosed.

This deal is too recent to grade. Critic Score and Outcome Score are assigned after the announcement-week coverage settles and, for Outcome, after the 5-year post-close assessment window opens — expected 2031 at the earliest for this deal, once/if it closes.

Key facts

Related deals

See the full interactive analysis, sources & comparables →

← Browse all deals  ·  How we score deals

More: 2026 deals  ·  Immunology deals